Latest news from the FASST trial
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
Read latest newsletter on the research: FASST Newsletter, May2016
news & events
Annelise, a Danish scleroderma patient for many years talks about the patient’s journey towards a diagnosis.
Meet António Pereira who has lived with and fought against Scleroderma for 40 years.
Meet Tânia Vieira who talks about the biggest passion many mothers can relate to.